Telegraph Hill Partners hires new venture partner

Telegraph Hill Partners has named Dr. Paul D. Grossman as a venture partner. Previously, Grossman worked at Life Technologies where he served as head of global strategy and corporate development. Based in San Francisco and San Diego, THP is a VC and growth equity firm that invests in life science and healthcare companies.

PRESS RELEASE

SAN FRANCISCO, CA–(Marketwired – Feb 10, 2014) – Telegraph Hill Partners (THP), a leading venture capital and growth equity firm dedicated exclusively to life science and healthcare investing, today announced the addition of Paul D. Grossman, Ph.D. to its investment team as a Venture Partner.
Dr. Grossman, a 32-year veteran of the life science industry, has extensive experience within the laboratory tools and instruments sector. Most recently, Dr. Grossman was Head of Global Strategy and Corporate Development at Life Technologies, Inc. In that role, he was responsible for spearheading the company’s corporate strategy, licensing, business development and acquisition activities. Dr. Grossman held the same position at Invitrogen Corporation prior to the merger with Applied Biosystems in 2008. Prior to joining Invitrogen, Dr. Grossman held a variety of leadership roles during his more than 25 years at Applied Biosystems, including research scientist, patent attorney, Vice President of Intellectual Property and Vice President of Strategy and Business Development. Dr. Grossman received bachelors and Ph.D. degrees in chemical engineering from the University of California, Berkeley, a master’s degree in chemical engineering from the University of Virginia, and a J.D. from Santa Clara University School of Law. He has authored numerous scientific publications and holds more than 20 U.S. patents.
“We are delighted to have Paul join our team. For over three decades Paul has been one of the leading innovators in the life science industry, initially as a scientist and later as a business strategist. Paul’s experience and insights will contribute to our investment decisions as we deploy our new fund, and will be a tremendous benefit to our portfolio companies,” said Matt Mackowski, Chairman of THP.
Dr. Grossman will be located in San Diego focused on developing new strategies, sourcing new opportunities and supporting the growth plans of existing THP portfolio companies.
About Telegraph Hill Partners
Telegraph Hill Partners, founded in 2001 and based in San Francisco and San Diego, CA, invests in commercial stage life science, medical technology and healthcare companies. THP manages $600M across three funds, and closed on THPIII with capital commitments of $310M in 2013. Further information concerning Telegraph Hill Partners may be found at www.telegraphhillpartners.com.

Related Posts

Leave a Reply

PEHUB Community

Join the 12500 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget